Hologic

Hologic's GYN Surgical Business to Drive Growth in Q1 Earnings

Hologic Inc. Buyout by Private Equity Remains on Track for 2026

Is Hologic's Share Price Undervalued?

Hologic to Release Q1 FY26 Earnings on January 29, 2026

Hologic Buyout Financing Tightens as Lenders Snap Up Loans

Catalyst<ul> <li>Most analysts rate HOLX Buy or Strong Buy, showing broad institutional optimism.</li> <li>The company maintains strong cash reserves relative to market value.</li> <li>Fund flows show small and medium-sized investors are currently injecting capital into HOLX.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state and the direction is not clear enough.</li> <li>Bearish signals are obviously dominant (1 bearish vs 0 bullish).</li> <li>Fund flows show large and extra-large investors are currently withdrawing capital from HOLX.</li></ul>

Key Factors

Hologic's take-private deal confirms a $79 per share offer, with $76 in cash at closing and a $3 per share contingent value right based on future revenue milestones for its Breast Health business. Hologic's buyout by private equity remains on track for 2026, with the company's US-based operations across diagnostics, breast health, surgical, and skeletal health segments. Hologic's GYN Surgical business drove a 10.2% revenue increase in the last quarter, fueled by MyoSure and Fluent sales and international Surgical unit performance.

HOLX News